Get the Stockscreener App
3.94
5.07%
0.19
Pre-market:
3.99
0.05
+1.27%
Vistagen Therapeutics Inc stock is traded at $3.94, with a volume of 231.51K.
It is up +5.07% in the last 24 hours and up +10.99% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$3.75
Open:
$3.77
24h Volume:
231.51K
Relative Volume:
0.39
Market Cap:
$120.88M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-2.9353
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
-3.19%
1M Performance:
+10.99%
6M Performance:
+68.38%
1Y Performance:
+27.92%
1-Day Range:
$3.7113
$3.97
1-Week Range:
$3.69
$4.11
52-Week Range:
$1.90
$4.52
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
3.94 | 115.05M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
Vistagen Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Strategies to average down on Vistagen Therapeutics Inc.Risk Management & Safe Entry Zone Identification - newser.com
Will breakout in Vistagen Therapeutics Inc. lead to full recoveryEarnings Miss & High Return Trade Opportunity Guides - newser.com
Is Vistagen Therapeutics Inc. a candidate for recovery play2025 Geopolitical Influence & Low Risk Entry Point Tips - newser.com
Will Vistagen Therapeutics Inc. stock benefit from green energy trends2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Should you hold or exit Vistagen Therapeutics Inc. nowWeekly Risk Summary & Weekly Watchlist for Hot Stocks - newser.com
Vistagen Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 Reactions & Intraday High Probability Setup Alerts - newser.com
Technical signs of recovery in Vistagen Therapeutics Inc.CPI Data & Community Consensus Stock Picks - newser.com
What dividend safety score for Vistagen Therapeutics Inc. stock2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
Will Vistagen Therapeutics Inc. stock gain from strong economy2025 Volatility Report & Fast Entry and Exit Trade Plans - newser.com
Is Vistagen Therapeutics Inc. stock reversal real or fakeRecession Risk & Community Consensus Trade Signals - newser.com
Published on: 2025-11-01 04:45:37 - newser.com
Combining machine learning predictions for Vistagen Therapeutics Inc.CEO Change & Reliable Price Action Trade Plans - newser.com
How to recover losses in Vistagen Therapeutics Inc. stockJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Will Vistagen Therapeutics Inc. stock remain a Wall Street favoriteForecast Cut & Precise Buy Zone Identification - newser.com
Is Vistagen Therapeutics Inc. stock a safe haven assetTrade Risk Assessment & Low Volatility Stock Suggestions - newser.com
How to escape a deep drawdown in Vistagen Therapeutics Inc.Day Trade & Low Risk Investment Opportunities - newser.com
VistaGen Therapeutics Appoints Paul R. Edick to Board - The Globe and Mail
Vistagen’s Promising Phase 2 Trial for Anxiety Treatment: A Market Game Changer? - MSN
Can Vistagen Therapeutics Inc. stock deliver surprise earnings beatJuly 2025 Catalysts & Real-Time Market Trend Scan - newser.com
Published on: 2025-10-30 03:05:01 - newser.com
VistaGen Therapeutics (VTGN) to Release Quarterly Earnings on Thursday - MarketBeat
Vistagen Therapeutics Appoints Paul R. Edick as Director - TradingView
Vistagen Appoints Paul Edick to Its Board of Directors, Audit Committee and the Compensation Committee - MarketScreener
Vistagen Appoints Paul Edick to its Board of Directors - Business Wire
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):